TNBC accounts for approximately 15 to 20% of all breast carcinomas.[2] Compared with hormone receptor-positive BCs, TNBC has a worse prognosis, with over 50% of patients experiencing a relapse in the first 3 to 5 years post-diagnosis, and the median overall survival (OS) based on current therapies is 10.2 months.[3]. Here, NR4A1 is linked to breast carcinoma.